Thyroid Cancer Diagnostics Market Report 2026

The thyroid cancer diagnostics market size has grown strongly in recent years. It will grow from $3.15 billion in 2025 to $3.34 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing incidence of thyroid nodules, wider availability of ultrasound imaging, improved biopsy techniques, expansion of cancer diagnostic laboratories, growing clinical awareness of thyroid cancers.

The thyroid cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing adoption of ai-assisted imaging diagnostics, rising demand for personalized oncology diagnostics, expansion of molecular testing panels, growing investments in early cancer screening, increasing focus on precision diagnostics. Major trends in the forecast period include increasing use of molecular diagnostic techniques, rising adoption of imaging-based screening, growing integration of genetic testing, expansion of early detection programs, enhanced diagnostic accuracy and speed.

The rising prevalence of thyroid cancer is expected to drive growth in the thyroid cancer diagnostics market in the coming years. Thyroid cancer affects the thyroid gland, located near the base of the throat, which produces hormones that regulate body temperature, heart rate, blood pressure, and weight. Diagnostic tools for thyroid cancer enable early detection, improving treatment outcomes and overall patient prognosis. The growing number of thyroid cancer cases is increasing demand for these diagnostic solutions. For example, in September 2023, the American Cancer Society, a US-based non-profit organization, reported an estimated 43,720 new thyroid cancer cases in 2023, including 12,540 in men and 31,180 in women. The projected deaths from thyroid cancer in the same year were around 2,120, with 970 in men and 1,150 in women. Therefore, the rising prevalence of thyroid cancer is driving growth in the diagnostic market.

Key companies in the thyroid cancer diagnostics market are developing innovative solutions, such as RNA sequencing tests, to improve the accuracy of detecting cancer-related gene fusions across various solid tumors, including thyroid cancer. RNA sequencing (RNA-Seq) is a high-throughput method that analyzes the quantity and sequence of RNA in a sample, offering detailed insights into gene expression and the transcriptome. For instance, in May 2024, Foundation Medicine, Inc., a US-based biotechnology company, launched FoundationOne RNA in the U.S., a tissue-based RNA sequencing test designed to detect gene fusions across 318 cancer-related genes. This test provides fusion reporting for all solid tumors and is particularly useful for identifying fusions in cancers such as non-small cell lung cancer (NSCLC), sarcoma, pancreatic cancer, thyroid cancer, cholangiocarcinoma, and bladder cancer.

In September 2024, the World Tumor Registry (WTR), a US-based non-profit organization focused on tumor data collection and analysis, partnered with PathPresenter to launch a global educational platform. This collaboration supports WTR’s mission to provide accessible, secure, and scalable educational resources for cancer care and research organizations worldwide, aimed at advancing cancer diagnostics and education. PathPresenter is a US-based multi-tenant enterprise pathology workflow software platform.

Major companies operating in the thyroid cancer diagnostics market are General Electric, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Toshiba Corporation, Siemens Healthcare GmbH, FUJIFILM Holdings Corporation, Koninklijke Philips N.V., Agilent Technologies Inc., Hologic Inc., Illumina Inc., BioMérieux SA, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., Qiagen N.V., Cepheid, Veracyte Inc., DiaSorin S.p.A., Myriad Genetics Inc., Interpace Biosciences, Guardant Health, BillionToOne, Canon Inc., Beckman Coulter Inc.

North America was the largest region in the thyroid cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thyroid cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the thyroid cancer diagnostics market by increasing costs of imported imaging systems, biopsy devices, molecular testing kits, and laboratory automation equipment. Diagnostic centers and hospital laboratories in North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces higher costs for advanced testing systems. These tariffs are increasing diagnostic service costs and delaying equipment upgrades. However, they are also supporting domestic diagnostic manufacturing, regional reagent production, and local innovation in cancer testing technologies.

The thyroid cancer diagnostics market research report is one of a series of new reports that provides thyroid cancer diagnostics market statistics, including thyroid cancer diagnostics industry global market size, regional shares, competitors with a thyroid cancer diagnostics market share, detailed thyroid cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer diagnostics industry. This thyroid cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thyroid cancer diagnostics refers to methods used to test lumps or nodules that may indicate thyroid cancer, aiding in the diagnosis of the disease. Thyroid cancer is a type of cancer that originates in the thyroid gland when cells begin to grow uncontrollably.

The main techniques in thyroid cancer diagnostics include imaging tests, blood tests, biopsies, and others. Imaging involves creating visual representations of phenomena such as temperature, sound waves, chemicals, or electrical activity. Imaging tests are used to produce images of the thyroid gland for diagnostic purposes. The various disease types include papillary carcinoma, follicular carcinoma, and others. These diagnostic techniques are employed by end-users such as hospital laboratories, cancer diagnostic centers, research institutes, and more.

The thyroid cancer diagnostics market includes revenues earned by entities by providing diagnostic tools related detection and diagnosis of thyroid cancer, radioactive tracer, biopsy, blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.